Autoplaque vs Discovery MI Gen2

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Autoplaque

by APQ Health (formerly Cedars-Sinai Medical Center: AIM)

Discovery MI Gen2

by GE HealthCare

AI Verdict

Autoplaque is a software tool designed for the quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, focusing on post-acquisition assessment. In contrast, Discovery MI Gen2 is a physical PET/CT imaging system that utilizes AI for enhanced image acquisition and reconstruction across multiple specialties including cardiology, oncology, and neurology. While both leverage AI within radiology and cardiology, Autoplaque specializes in image analysis, whereas Discovery MI Gen2 focuses on advanced image generation.

Choose Autoplaque if…

Choose Autoplaque if your primary need is a detailed, AI-powered quantitative analysis of existing CT angiography (CTA) images to assess coronary plaque burden and luminal stenoses. This workstation-based software is ideal for cardiologists and radiologists seeking to enhance heart attack risk prediction and guide treatment decisions through precise, automated measurements of coronary anatomy and pathology.

View Autoplaque →

Choose Discovery MI Gen2 if…

Choose Discovery MI Gen2 if your facility requires a cutting-edge, on-premise digital PET/CT system for comprehensive diagnostic imaging across oncology, neurology, and cardiology. This system is particularly well-suited for scenarios demanding superior image quality, improved small lesion detectability, and reduced scan times or injected dose, leveraging deep-learning AI and advanced motion correction for optimal patient outcomes.

View Discovery MI Gen2 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Autoplaque	Discovery MI Gen2
Pricing	Unknown	Contact vendor for pricing
Deployment	Workstation-based post-processing application, runs on Windows or Mac OS.	On-premise (physical hardware)
FDA Status	Cleared AI-estimated	Cleared AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Autoplaque

Tool A, Autoplaque, is described as workstation-based software with automated segmentation that is reviewable and editable by clinicians, directly addressing user interaction with the AI's analytical output. This focus on clinician review and editing capabilities suggests a user-centric design for interpreting AI results. Tool B, Discovery MI Gen2, focuses more on automated patient positioning and reduced scan times, which improves operational efficiency and patient experience rather than direct clinician interaction with AI analysis.

Clinical Value

Discovery MI Gen2

Tool B, Discovery MI Gen2, offers superior diagnostic imaging across oncology, neurology, and cardiology, with key features like improved small lesion detectability and accurate SUV measurements. This provides broad and fundamental improvements in diagnostic capabilities for multiple critical disease areas. While Tool A provides valuable quantitative analysis for heart attack risk, Tool B's impact on overall diagnostic accuracy and scope is more extensive.

Pricing & Value

Tie

Tool A's pricing is not disclosed, making a direct comparison of value impossible. Tool B is an ultra-premium tier physical PET/CT system with a price range of $950,000-$1,900,000 for refurbished systems, representing a significant capital investment. Without knowing Tool A's cost, it is not possible to definitively determine which offers better value.

Enterprise Readiness

Discovery MI Gen2

Tool B is developed by GE HealthCare, a global leader in medical technology, implying robust enterprise support, established compliance frameworks, and extensive integration capabilities. Tool A, developed by Cedars-Sinai AIM, while a reputable institution, is not primarily a commercial software vendor, and its enterprise support structure for widespread commercial deployment is likely less mature. GE HealthCare's established presence and infrastructure provide a stronger foundation for enterprise readiness.

Innovation

Discovery MI Gen2

Tool B, Discovery MI Gen2, demonstrates broader innovation by integrating deep-learning AI with advanced hardware components like the LightBurst Digital Detector and MotionFree digital respiratory motion management. This holistic approach enhances the entire PET/CT imaging modality, leading to improvements in sensitivity, image reconstruction, and motion correction. Tool A's innovation is focused on a specialized AI application for coronary plaque analysis, which is significant but narrower in scope compared to Tool B's system-wide advancements.

Support & Docs

Discovery MI Gen2

As a major medical device manufacturer, GE HealthCare (Tool B) is expected to provide comprehensive global support, training, and documentation for its complex imaging systems. For Autoplaque (Tool A), developed by a medical center, the level of commercial support and documentation is not specified and is likely less extensive or formalized than that offered by a dedicated commercial vendor like GE HealthCare.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Autoplaque	Discovery MI Gen2
Product Name	Autoplaque	Discovery MI Gen2
Company	Cedars-Sinai Medical Center: AIM	GE HealthCare
Primary Function	AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance.	Next-generation digital PET/CT system that leverages deep-learning AI, high sensitivity, and advanced motion correction to deliver superior diagnostic imaging for oncology, neurology, and cardiology.
Core AI Application	AI-powered quantitative analysis of atherosclerotic plaque, detection and characterization of coronary artery plaque, measurement of luminal stenoses, automated vessel, plaque, and lumen segmentation.	TrueFidelityu2122 deep-learning based image reconstruction, Q.Clear quantitation for accurate SUV measurements and noise reduction, MotionFree digital respiratory motion management solution.
Target Specialties	Cardiology, Radiology	Nuclear Medicine, Oncology, Radiology

Videos

Demos, reviews, and walkthroughs featuring Autoplaque and Discovery MI Gen2.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate with our existing imaging workflows and PACS/RIS systems to ensure seamless data flow and reporting?

Autoplaque is a workstation-based post-processing application that analyzes CT angiography images, and its output would typically integrate with PACS and EHR for reporting. Discovery MI Gen2, as a PET/CT system, generates images and quantitative data that are sent to PACS and then integrated into the EHR, with features like automated patient positioning to streamline acquisition workflow.

For a cardiology practice, what specific clinical insights or diagnostic advantages does each tool offer that are not achievable with current standard-of-care methods?

Autoplaque provides AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance by characterizing dangerous plaque and stenosis quantification. Discovery MI Gen2 offers high sensitivity, deep-learning image reconstruction, and motion correction for superior diagnostic imaging, which can lead to improved small lesion detectability and accurate SUV measurements in cardiology, oncology, and neurology.

What evidence supports the quantitative accuracy and reliability of the measurements and analyses provided by each tool, especially for critical clinical decision-making?

Autoplaque has demonstrated excellent intra- and inter-reader reproducibility for measurements of calcified plaque volume, low-attenuation plaque volume, and pericoronary adipose tissue volume. Discovery MI Gen2 features Q.Clear quantitation, which provides up to a 2x improvement in PET quantitation accuracy (SUVmean) and image quality (SNR), and has shown up to a 41% increase in small lesion detectability.

What is the expected learning curve for radiologists, cardiologists, and technologists to become proficient with each system, and what training resources are provided?

Autoplaque is workstation-based software with automated segmentation that is reviewable and editable by clinicians, suggesting a learning curve for interacting with the AI's output. Discovery MI Gen2, as a new PET/CT system, would require training for technologists on operating the scanner and for radiologists on interpreting images enhanced by deep-learning reconstruction and motion correction.

What level of ongoing technical and clinical support is provided, and can you facilitate connections with current users who have implemented these tools in similar clinical environments?

While specific details on customer references are not provided, GE HealthCare offers a customer documentation portal for product manuals, support, and education, including information on interoperability and product security. Cedars-Sinai, as the developer of Autoplaque, offers contact information for support.

Beyond standard compliance, what advanced security features protect patient data within the tool, and what audit-trail capabilities are available to track usage and data modifications?

The provided information does not detail advanced security features beyond HIPAA compliance for either tool, nor does it explicitly outline audit-trail capabilities. However, audit trails are crucial for data integrity, accountability, and traceability in regulated environments.

What are the primary considerations and potential challenges for deploying each tool across multiple hospital sites or clinics within an integrated health system?

For Autoplaque, a workstation-based software, multi-site deployment would involve installing the software on multiple Windows or Mac computer platforms. For Discovery MI Gen2, an on-premise physical hardware system, multi-site rollout would entail significant logistical planning for installation, site preparation, and capital investment at each location.